|Summary sheet: DET|
|Common names||Diethyltryptamine, DET|
|Routes of Administration|
Diethyltryptamine (also known as N,N-DET or DET) is a synthetic psychedelic tryptamine and a close structural analog of DMT (Dimethyltryptamine). It is extremely uncommon and has little history of human usage.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
DET, or N,N-diethyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. DMT contains two ethyl groups CH2CH3- bound to the terminal amine RN of its tryptamine backbone. DET has many substituted analogues such as 4-HO-DET ("ethocin").
Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other tryptamine psychedelics such as psilocin and DMT. With this in mind, DET is thought to act as an 5-HT2A partial agonist.
Unlike DMT, the ethyl groups add protection against the monoamine oxidase enzyme system, allowing DET to be orally active, while DMT is not.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently 0 anecdotal reports which describe the effects of this compound within our experience index.
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational DET has not been studied in any scientific context and the exact toxic dose is unknown. This is because DET is a research chemical with a limited history of human usage. However, it is presumed to have a similar toxicity profile as DMT due to similarities in their chemical structure.
Anecdotal reports from those who have tried DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
Although no formal studies have been conducted, it is believed that DET is not habit-forming and the desire to use it can actually decrease with use.
Tolerance to the effects of DET is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). DET presents cross-tolerance with all psychedelics, meaning that after the consumption of DET all psychedelics will have a reduced effect.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Lithium - Lithium is often used as treatment for bipolar disorder. It can dangerously amplify the intensity of psychedelics and has been strongly linked with psychosis and seizures. The causes are poorly understood, but it may be due to its glutaminergic and GABAergic properties.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in those who are predisposed to them.
- Germany: DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 24, 1974. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Italy: DET is a Schedule I controlled substance.
- New Zealand: DET is a Class A controlled substance in New Zealand.
- Switzerland: DET is a controlled substance specifically named under Verzeichnis D.
- United Kingdom: DET is a Class A controlled substance.
- United States: DET is a Schedule I controlled substance.
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in German). Bundesanzeiger Verlag. January 23, 1974. pp. 97–98. Retrieved January 7, 2020.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- "Tabella I" (PDF) (in Italian). Ministero della Salute [Ministry of Health]. p. 8. Retrieved January 7, 2020.
- "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.
- "Controlled Substances: by CSA Schedule" (PDF). U.S. Department of Justice. August 21, 2019. p. 4. Retrieved January 7, 2020.